Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	US$1.550	+6.16%	87,577
26-08-13	US$1.460	+1.39%	25,271
26-08-12	US$1.440	-2.04%	19,937
26-08-11	US$1.470	+0.68%	16,360
26-08-10	US$1.460	+6.57%	27,729

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.550USD

Average target price

25.00USD

Spread / Average Target

+1,512.90%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
1.550 ^USD	+6.16%		+13.14%	-14.84%

08-04	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-22	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI

Market Cap	7.43M 6.41M 6.03M 5.48M 10.31M 710M 10.48M 70.63M 27.61M 356M 27.88M 27.28M 1.18B	P/E 2027 *	-0.6x	P/E 2028 *	-
Enterprise Value	7.43M 6.41M 6.03M 5.48M 10.31M 710M 10.48M 70.63M 27.61M 356M 27.88M 27.28M 1.18B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.32%	Yield 2027 *	-	Yield 2028 *	-

08-04	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-22	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
07-21	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
07-21	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
03-16	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
03-16	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
03-11	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
03-06	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE
12-09	Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025	CI
11-19	Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 Lithium in Brain Study Conducted at Massachusetts General Hospital	CI
11-19	Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital	RE

23-04-12	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
21-12-27	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
21-10-01	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Stock

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news : Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-22	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
04-07	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
03-26	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR
03-16	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	PR
11-19	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital	PR

1 day	+6.16%
1 week	+13.14%
Current month	+18.32%
1 month	+27.05%
3 months	+51.96%
6 months	-4.91%
Current year	-14.84%

1 week	1.41	1.55
1 month	1.18	1.55
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	405
5 years	0.84	4,819.5
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	2018-11-19
David Katzoff DFI	Director of Finance/CFO	64	2022-08-04
Henry Nisser LAW	General Counsel	57	2019-04-30

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	2016-02-25
William Horne CHM	Chairman	57	2021-05-31
Stephan Jackman BRD	Director/Board Member	50	2020-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.9364%
7/31/26	Todd Ault	Other	Founder	0	0%
7/31/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.9364%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+6.16%	+13.14%	-34.74%	-99.60%	7.43M
LONZA GROUP AG	+0.14%	-2.93%	+1.22%	+18.89%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+581.30%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+80.67%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+9.97%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+126.36%	16.15B
EUROFINS SCIENTIFIC SE	-1.45%	-0.89%	+3.09%	+26.68%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+38.66%	13.37B
Average	+0.02%	+1.00%	+65.35%	+93.46%	26.32B
Weighted average by Cap.	-0.66%	-0.62%	+95.72%	+140.59%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.33M -8.77M -7.97M -14.99M -1.03B -15.23M -103M -40.16M -517M -40.55M -39.67M -1.72B	-
Net Debt	-	-